These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22243688)

  • 21. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
    Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
    Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB.
    Laje G; Cannon DM; Allen AS; Klaver JM; Peck SA; Liu X; Manji HK; Drevets WC; McMahon FJ
    Int J Neuropsychopharmacol; 2010 Jul; 13(6):715-24. PubMed ID: 20047709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of action of antidepressants.
    Artigas F; Nutt DJ; Shelton R
    Psychopharmacol Bull; 2002; 36 Suppl 2():123-32. PubMed ID: 12490828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia.
    McManus P; Mant A; Mitchell P; Dudley J
    Aust N Z J Psychiatry; 2004 Jun; 38(6):450-4. PubMed ID: 15209838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study.
    Posternak MA; Zimmerman M
    J Clin Psychiatry; 2005 Jun; 66(6):705-7. PubMed ID: 15960562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dose-finding study of duloxetine based on serotonin transporter occupancy.
    Takano A; Suzuki K; Kosaka J; Ota M; Nozaki S; Ikoma Y; Tanada S; Suhara T
    Psychopharmacology (Berl); 2006 Apr; 185(3):395-9. PubMed ID: 16506079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Fluoxetine: an update of its use in major depressive disorder in adults].
    Gourion D; Perrin E; Quintin P
    Encephale; 2004; 30(4):392-9. PubMed ID: 15597466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: A positron emission tomography study with [(11)C]DASB.
    Arakawa R; Tateno A; Kim W; Sakayori T; Ogawa K; Okubo Y
    Psychiatry Res Neuroimaging; 2016 May; 251():1-6. PubMed ID: 27082864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does the use of SSRIs reduce medical care utilization and expenditures?
    Chung S
    J Ment Health Policy Econ; 2005 Sep; 8(3):119-29. PubMed ID: 16278500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.
    Kim H; Lim SW; Kim S; Kim JW; Chang YH; Carroll BJ; Kim DK
    JAMA; 2006 Oct; 296(13):1609-18. PubMed ID: 17018806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants.
    Perry PJ
    J Affect Disord; 1996 Jun; 39(1):1-6. PubMed ID: 8835647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials.
    Machado M; Iskedjian M; Ruiz I; Einarson TR
    Curr Med Res Opin; 2006 Sep; 22(9):1825-37. PubMed ID: 16968586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence of a role for the 5-HTTLPR genotype in the modulation of motor response to antidepressant treatment.
    Putzhammer A; Schoeler A; Rohrmeier T; Sand P; Hajak G; Eichhammer P
    Psychopharmacology (Berl); 2005 Mar; 178(2-3):303-8. PubMed ID: 15322730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.
    Anderson IM
    J Affect Disord; 2000 Apr; 58(1):19-36. PubMed ID: 10760555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures.
    Verdel BM; Souverein PC; Egberts TC; van Staa TP; Leufkens HG; de Vries F
    Bone; 2010 Sep; 47(3):604-9. PubMed ID: 20601295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures.
    Ziere G; Dieleman JP; van der Cammen TJ; Hofman A; Pols HA; Stricker BH
    J Clin Psychopharmacol; 2008 Aug; 28(4):411-7. PubMed ID: 18626268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder.
    Ruhé HG; Ooteman W; Booij J; Michel MC; Moeton M; Baas F; Schene AH
    Pharmacogenet Genomics; 2009 Jan; 19(1):67-76. PubMed ID: 18987562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it?
    McManus P; Mant A; Mitchell P; Birkett D; Dudley J
    Br J Clin Pharmacol; 2001 Jan; 51(1):93-8. PubMed ID: 11167670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.